| Literature DB >> 29853954 |
Rebeca Ebelle Etame1, Raymond Simplice Mouokeu2, Cedric Laurel Cidjeu Pouaha3, Igor Voukeng Kenfack4, Raphael Tchientcheu3, Jean Paul Assam Assam3, Frank Stève Monthe Poundeu3, Alembert Tchinda Tiabou1, François Xavier Etoa5, Jules Roger Kuiate4, Rosalie Anne Ngono Ngane3.
Abstract
Infectious diseases caused by bacteria constitute the main cause of morbidity and mortality throughout the world and mainly in developing countries. In this work, the influence of fractioning and the mode of action of stem barks methanol extract of Enantia chlorantha were investigated. The aim was to optimize the antibacterial activity of the methanol extract. The extract was prepared by maceration of barks powder in methanol. Fractioning was done using increasing solvents polarity. Standard phytochemical methods were used for phytochemical screening. Minimum Inhibitory Concentrations (MIC) and Minimum Bactericidal Concentration (MBC) of the methanol extract and fractions were determined using broth microdilution method. The studied mode of action of both methanol extract and n-butanol fraction included antibiofilm activity, H+-ATPase-mediated proton pumping assay, salt tolerance, and cells cycle. The methanol extract of E. chlorantha stem barks was found to be active on all the bacteria tested (32 ≤ MIC ≤ 512 μg/mL), its activity being significant (MIC < 100 μg/ml) out of 5 of the 28 clinical isolates used. Salmonella enterica serovar paratyphi A was the most sensitive (32 μg/mL). Compared to the extract and other fractions, the n-butanol fraction was found to be more active (32 ≤ MIC ≤ 256). Significant antibacterial activity of this fraction was observed out of 10 of the 28 bacterial isolates and 3 out of 7 bacterial strains. Lowest MIC values (32 μg/ml) of this fraction were obtained with Escherichia coli (136), Pseudomonas aeruginosa (CIP 76110), and Salmonella enterica serovar typhi 9. The methanol extract of E. chlorantha and its n-butanol fraction revealed several modes of action including the prolongation of the latency phase of the bacterial growth, the inhibition of the pump with protons H+ - ATPases bacterial, the loss of the salt tolerance of the Staphylococcus aureus, and inhibition of the formation of the bacterial biofilm. The present results showed that the n-butanol fraction of the methanol stem barks extract of E. chlorantha possess the essential antibacterial components and could best be used to fight against bacterial infections as compared to methanol extract.Entities:
Year: 2018 PMID: 29853954 PMCID: PMC5949159 DOI: 10.1155/2018/4831593
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Bacteria strains and clinical isolates feature used in the study.
| Bacteria | Characteristics | References |
|---|---|---|
|
| ||
|
| ||
|
| [ | |
| ATCC10536 | Reference strains | |
| E.C 96 | Clinical isolate: IPMS, AMCI, NORS, CFMS, CROR, CIPS, ANI, CHLS | |
| E.C 99 | Clinical isolate: IPMS, AMCI, NORS, CFMS, CROS, CIPS, ANI, CHLS | |
| E.C 136 | Clinical isolate: IPMS, AMCR, NORS, CFMS, CROS, CIPS, ANS, CHLS | |
| E.C 137 | Clinical isolate: IPMS, AMCS, NORS, CFMS, CROS, CIPS, ANI, CHLS | |
| E.C 146 | Clinical isolate: IPMS, AMCR, NORS, CFMS, CROR, CIPS, ANI, CHLS | |
|
| ||
| ATCC 13048 | Reference strains | |
| ENT 118 | Clinical isolate: IPMS, AMCR, NORS, CFMS, CROS, CIPS, ANS, CHLS | |
| ENT 119 | Clinical isolate: IPMS, AMCI, NORS, CFMS, CROS, CIPS, ANI, CHLS | |
| ENT 144 | Clinical isolate: IPMS, AMCR, NORR, CFMS, CROS, CIPS, CHLR | |
|
| ||
| ATCC 11296 | Reference strains | |
| KL 111 | Clinical isolate: IPMS, AMCI, NORS, CFMS, CROI, CIPS, ANI, CHLS | |
| KL 128 | Clinical isolate: IPMS, AMCR, NORS, CFMS, CROS, CIPS, ANS, CHLS | |
|
| ||
| ATCC 6539 | Reference strains | |
| SAL 9 | Clinical isolate: IPMS, AMCR, NORS, CFMS, CROR, CIPS, ANI, CHLI | |
| SAL 21 | Clinical isolate: IPMS, AMCI, NORS, CFMR, CROS, CIPS, ANS, CHLI | |
|
| ||
|
| Clinical isolate: AMR, TER, SXTR, NAR, CIPS, CHLS | [ |
|
| Clinical isolate: AMR, TER, SXTR, NAR, CIPS, CHLS | |
|
| Clinical isolate: AMR, TER, SXTR, NAR, CIPS, CHLS | |
|
| ||
|
| ||
| ATCC 27853 | Reference strains | |
| CIP 76110 | Reference strains | |
|
| ||
|
| [ | |
| PS 2636 | Clinical MDR isolate, AcrAB-TolC | |
| NEA 16 | Clinical MDR isolate, AcrAB-TolC | |
|
| ||
|
| ||
|
| ||
|
| [ | |
| ATCC 25923 | Reference strains | |
| MRSA 9 | Clinical multidrug isolate: OFXR, FLXR, KR, ER, CHLR, IMP/CSR | |
| MRSA 11 | Clinical multidrug isolate: OFXR, KR, ER, CIPR, IM/CSR | |
| MRSA 12 | Clinical multidrug isolate: OFXR, FLXR, KR, ER, IM/CSR | |
| MRSA 3 | Clinical multidrug isolate: OFXR, KR, ER, TER | |
| MRSA 4 | Clinical multidrug isolate: OFXR, KR, CHLR, CIPR | |
|
| ||
| ST 9 | Clinical isolate: IPMS, AMCS, AMS, DOS, VAS | [ |
| ST 60 | Clinical isolate: IPMS, AMCS, AMS, DOS, VAS, ES | |
| ST 113 | Clinical isolate: IPMS, AMCS, AMS, DOS, VAS, ES | |
| ST 118 | Clinical isolate: IPMS, AMCS, AMS, DOS, VAS, ES | |
| ST 120 | Clinical isolate: IPMS, AMCS, AMS, DOS, VAS, ES | |
| ST 130 | Clinical isolate: IPMS, AMCS, AMS, DOS, VAS, ES | |
AN: amikacin, AM: ampicillin, AMC: amoxicillin-clavulanate, CHL: chloramphenicol, CFM: cefixime, CIP: ciprofloxacin, CRO: ceftriaxone, DO: doxycyclin, E: erythromycin, FLX: flomoxef, IMP: imipenem, IM/CS: imipenem/cilastatin sodium, K: kanamycin, NA: nalidixic acid, NOR: norfloxacin, OFX: ofloxacin, TE: tetracycline, SXT: trimethoprim-sulfamethoxazole, VA: vancomycin. R: resistant, S: sensible, and I: intermediate.
Effect of fractioning of E. chlorantha methanol extract on MICs/MBCs (μg/mL) values.
| Bacteria | Extract | n-Hexane | Ethyl acetate | n-Butanol | Residual | CHL |
|---|---|---|---|---|---|---|
|
| ||||||
| ATCC 10536 | 128/256 | 512/- | 256/1024 | 128/256 | 128/512 | 4/64 |
| EC 136 | 128/512 | 512/- | 256/512 | 32/256 | 64/512 | 32/256 |
| EC 137 | 128/256 | 1024/- | 256/1024 | 64/256 | 64/512 | 64/- |
| EC 99 | 128/256 | 1024/- | 128/512 | 64/256 | 64/512 | 32/128 |
| EC 96 | 512/1024 | 512/- | 256/- | 128/256 | 256/512 | 32/128 |
| EC 146 | 64/128 | 512/- | 1024/- | 128/256 | 512/1024 | 32/256 |
|
| ||||||
| ATCC 13048 | 128/256 | 256/- | 512/- | 256/512 | 256/256 | 8/128 |
| ENT 119 | 64/1024 | 256/1024 | 256/1024 | 64/512 | 128/512 | 16/128 |
| ENT 118 | 512/1024 | 1024/- | 256/- | 128/1024 | 256/1024 | 128/- |
| ENT 144 | 128/256 | 1024/- | 512/- | 256/256 | 256/512 | 32/64 |
|
| ||||||
| ATCC 11296 | 128/512 | 512/- | 256/- | 128/512 | 128/512 | 8/64 |
| KL 128 | 128/512 | 1024/- | 256/- | 64/256 | 32/256 | 32/128 |
| KL 111 | 128/512 | 1024/- | 256/1024 | 128/512 | 256/512 | 32/- |
|
| 32/256 | 128/512 | 128/512 | 64/256 | 256/1024 | 16/64 |
|
| 128/512 | 256/- | 64/1024 | 64/128 | 128/1024 | 8/128 |
|
| 128/- | -/- | -/- | 256/- | 512/- | 32/128 |
|
| ||||||
| ATCC 6539 | 128/512 | 512/1024 | 256/- | 64/256 | 128/1024 | 64/256 |
| SAL 9 | 128/512 | 512/1024 | 512/- | 32/512 | 128/1024 | 32/128 |
| SAL 21 | 256/512 | 512/- | 256/- | 128/512 | 128/- | 64/- |
|
| ||||||
| ATCC 27853 | 128/512 | 256/- | 1024/- | 128/512 | 128/512 | 16/128 |
| CIP 76110 | 128/1024 | 256/- | 64/- | 32/256 | 32/256 | 4/32 |
|
| ||||||
| PS 2636 | 128/1024 | -/- | -/- | 256/- | 512/- | 32/- |
| NEA 16 | 64/- | -/- | -/- | 256/- | 256/- | 8/256 |
|
| ||||||
| ATCC 25923 | 256/512 | 512/- | 256/512 | 128/256 | 128/512 | 32/128 |
| ST 120 | 64/512 | -/- | 512/512 | 64/256 | 64/512 | 8/64 |
| ST 113 | 128/- | 1024/- | 256/- | 64/512 | 128/- | 16/64 |
| ST 9 | 256/1024 | 512/- | 256/- | 128/256 | 128/- | 32128 |
| ST 118 | 256/1024 | 1024/- | 256/- | 128/1024 | 256/512 | 64/128 |
| ST 130 | 128/512 | 512/- | 128/1024 | 128/1024 | 128/1024 | 4/64 |
| ST 60 | 256/1024 | 1024/- | 128/- | 64/512 | 64/- | 8/128 |
| MRSA 9 | 256/512 | 1024/- | 1024/- | 128/512 | 512/- | 128/- |
| MRSA 11 | 256/1024 | 512/- | 512/- | 128/512 | 512/1024 | 32/128 |
| MRSA 12 | 512/1024 | 1024/- | 512/- | 128/1024 | 256/- | 64/64 |
| MRSA 4 | 256/- | -/- | -/- | 256/- | 256/- | 8/64 |
| MRSA 3 | 256/- | -/- | -/- | 256/- | 512/- | 32/128 |
CHL = chloramphenicol, - = MIC or MBC was greater than 1024.
Figure 1Effect of E. chlorantha methanol extract (a) and its n-butanol fraction (b) on Staphylococcus aureus growth as a function of time. CHL: chloramphenicol; MIC: minimum inhibitory concentration. Data are expressed as mea, n = 3.
Figure 2Effect of E. chlorantha methanol extract (a) and its n-butanol fraction (b) on Escherichia coli growth as a function of time. CHL: chloramphenicol; MIC: minimum inhibitory concentration. Data are expressed as mean; n = 3.
Figure 3Effect of E. chlorantha methanol extract (a) and its n-butanol fraction (b) on Staphylococcus aureus proton pumping. MIC: minimum inhibitory concentration; data are expressed as mean ± SEM n = 3; Ph was measured after 10 min preincubation.
Figure 4Effect of E. chlorantha methanol extract (a) and its n-butanol fraction (b) on Escherichia coli proton pumping. MIC: minimum inhibitory concentration; data are expressed as mean ± SEM n = 3; Ph was measured after 10 min preincubation.
Figure 5Effect of E. chlorantha methanol extract (a) and its n-butanol fraction (b) on the reduction of salt tolerance of Staphylococcus aureus. MIC: minimum inhibitory concentration; data are expressed as mean ± SEM n = 3. Values with different superscript letters are significantly different at p < 0.05 according to Waller Duncan.
Figure 6Antibiofilm effect of E. chlorantha methanol extract (a) and its n-butanol fraction (b) against Escherichia coli (EC 136). MIC: minimum inhibitory concentration; data are expressed as mean ± SEM n = 3. Values with different superscript letters are significantly different at p < 0.05 according to Waller Duncan.
Extraction yields and phytochemical composition of methanol extract and fractions from E. chlorantha barks.
| Phytochemical groups | Crude extract (7.91%) | Fractions | |||
|---|---|---|---|---|---|
| FH (5.66%) | FAE (12.5%) | FBU (20.87%) | FR (39.71%) | ||
| Alkaloids | + | − | + | + | + |
| Anthocyanins | − | − | − | − | − |
| Flavonoids | + | − | + | + | + |
| Phenols | + | − | − | + | + |
| Quinones | + | − | + | + | + |
| Saponins | − | − | − | − | − |
| Tannins | + | − | − | + | + |
| Sterols | + | − | + | + | + |
| Triterpenes | + | + | + | + | − |
+: presence; −: absence, FH: n-hexane fraction, FAE: ethyl acetate fraction, FBU: n-butanol fraction, and FR: residual fraction.